Loading clinical trials...

Controlled Study of ONO-5920 in Patients With Involutional Osteoporosis in Japan | Clinical Trials | Clareo Health

COMPLETEDPHASE3

Controlled Study of ONO-5920 in Patients With Involutional Osteoporosis in Japan

NCT00212719•Ono Pharmaceutical Co. Ltd

Summary

The purpose of this study is to evaluate the efficacy and safety of ONO-5920 in patients with involutional osteoporosis.

Eligibility

Age

45 - No limit years

Sex

FEMALE

Healthy Volunteers

Inclusion Criteria

•1. A diagnosis in accordance with Criteria for the Diagnosis of Primary Osteoporosis.

Exclusion Criteria

•1. Patients having secondary osteoporosis or another condition that presents low bone mass.
•2. Patients having findings that affect measurement of lumbar spinal bone mineral density by DXA
•3. Patients that have been administered bisphosphonate derivatives.

Key Dates

Start Date

May 1, 2003

Primary Completion Date

April 1, 2006

Last Updated

October 11, 2012

Enrollment

250

Estimated participants

Conditions

Involutional Osteoporosis

Interventions

ONO-5920

DRUG

Controlled Study of ONO-5920 in Patients With Involutional Osteoporosis in Japan

NCT00212628

Involutional Osteoporosis

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: October 11, 2012Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions